102
Management
Table 25. Recommended Monitoring for Patients Taking Other
Antiarrhythmic Drugs
Drug Baseline Testing Follow-Up Testing
Additional Follow-
Up Testing
Dofetilide 12-lead ECG*
Continuous ECG
monitoring during
3-d hospitalization
for dofetilide
initiation
Serum potassium
and magnesium
concentration
Serum creatinine for
estimation of CrCl
In 3–6 mo:
12-lead ECG*
Serum potassium
and magnesium
concentration
Serum creatinine for
estimation of CrCl
Every 3–6 mo
(more frequently
for patients
concomitantly
taking other QT
interval-prolonging
drugs or with
changing kidney
function):
12-lead ECG*
Serum potassium
and magnesium
concentration
Serum creatinine for
estimation of CrCl
Dronedarone 12-lead ECG*
AST
†
ALT
†
Within first 6 mo:
AST
†
ALT
†
—
Ibutilide 12-lead ECG*
Determination of
serum potassium
and magnesium
concentrations
and correction of
hypokalemia and/or
hypomagnesemia is
recommended prior
to initiation of the
infusion
Continuous ECG
monitoring for
assessment of QTc
interval duration is
recommended for at
least 4 h following
infusion or until the
QTc has returned to
baseline to minimize
the risk of ibutilide-
associated TdP
—
